<DOC>
	<DOCNO>NCT00543387</DOCNO>
	<brief_summary>This study investigate safety , side effect well body tolerate MK-5108 well determine different dos MK-5108 participant advance and/or refractory solid tumor .</brief_summary>
	<brief_title>Treatment Participants With Advanced and/or Refractory Solid Tumors ( MK-5108-001 AM4 )</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Participant histologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy progress standard therapy Participant chemotherapy , radiotherapy biological therapy within 4 week prior study start recover adverse event cause therapy 4 week earlier Participant currently participate participate study investigational compound device within 4 week prior sign inform consent Participant receive 2 course chemotherapy metastatic disease Participant prolong neutropenia neutropenia fever previous chemotherapy treatment Participant primary central nervous system tumor Participant regular recreational user illicit drug recent history within last year drug alcohol abuse Participant pregnant , breastfeed plan child study Participant Human Immunodeficiency Virus ( HIV ) positive Participant history Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>